Cutting-edge News:
1 M€ fund-raising for TheraSonic with Gustave Roussy onboard !!!!
This fund-raising is led by the European venture studio M2care, created at the initiative of Mérieux Développement, a specialist in healthtech, and associated with the project for a year prior to its creation. Gustave Roussy Transfert, a company dedicated to innovation and technology transfer, and a subsidiary of Gustave Roussy, Europe's leading cancer research center, is also investing in TheraSonic, to provide access to unique clinical expertise and ensure the earliest possible technological transition to the first patients.
TheraSonic is a Medtech start-up whose ambition is to transform the treatment of neurological diseases by improving drug delivery to the brain. The startup will initially address brain metastases, which affect more than 30,000 new people every year in France. The treatment of brain cancers represents a market worth almost $4 billion in 2023, and could reach $7 billion by 2033, driven by the rising incidence of cancer and improved treatments for peripheral tumors.
To meet this strong medical need, TheraSonic is developing a medical robot that enables the targeted delivery of ultrasound to the brain without surgery or anesthesia, during short therapeutic sessions. Combined with the intravenous injection of microbubbles, these focused ultrasounds induce a transient increase in the permeability of cerebral blood vessels, enabling drugs to reach their targets in the brain.
TheraSonic was co-founded by Benoit Larrat and Anthony Novell, who have combined nearly 30 years of research into therapeutic ultrasound at the CEA (Atomic Energy Center) and CNRS (National Center for Scientific Research) respectively, and have invested over €3 million in the field since 2010. Their work has resulted in several patents and over 40 international scientific publications. Over the past 3 years, the company's project has benefited from the CEA's Magellan business start-up support program. The founding team is complemented by the M2care venture studio, which provides human support, with the involvement of 6 people and a financial investment of over 900 k€.
In autumn 2023, TheraSonic has been selected by the Paris-Saclay Cancer Cluster to support its development. As such, TheraSonic benefits from privileged access to the cancer ecosystem (training courses, network of experts, offices, clinical trials, etc.).
Benoit Larrat, President and co-founder of TheraSonic, comments: "This first financing round provides us with the resources we need to rapidly implement the first clinical trial of our technology, with the aim of bringing its benefits to patients as quickly as possible. In this context, the choice of the venture studio model is an appropriate one, as it contributes to the company's development by providing expertise complementary to scientific and medical skills, and enables us to focus our initial recruitment on the technology."
(more in comments...)
📰 La startup #TheraSonic, créée fin 2023 et issue du CEA, annonce une levée de fonds d’1 million d’euros pour financer le développement de son dispositif médical robotisé conçu pour améliorer la délivrance de médicaments dans le cerveau grâce à l'utilisation d'ultrasons focalisés.
Lire le communiqué de presse ⤵️
TheraSonic, spin-off du CEA créée fin 2023, clôt une levée de fonds menée par le venture studio M2care pour développer une technologie révolutionnaire visant à améliorer la délivrance de médicaments dans le cerveau | Gustave Roussy
gustaveroussy.fr
Conseiller à la clientèle CIEPP chez FER Genève
6moJe suis impressionné par la vision de Marc Thurner et sa capacité à naviguer à travers des défis complexes. Mimix est en passe d'améliorer la vie de nombreuses personnes, et cela pourrait concerner n’importe lequel d’entre nous. Bravo à toi, à ton équipe, et à tous ceux qui vont saisir cette opportunité!